Literature DB >> 15710382

p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.

Steven A Innocente1, Jonathan M Lee.   

Abstract

The p53 tumour suppressor protein is a DNA-binding transcription factor activated in response to DNA damage. Inactivation of the p53 gene occurs in 40-60% of human tumours and a substantial body of work indicates that loss of p53 activity is a critical step in oncogenesis. p53 helps to protect against neoplasia by inducing death in cells that have sustained irreparable DNA damage or by blocking cell cycle progression to allow time for DNA repair. We have previously reported that p53 prevents G2/M transition by decreasing intracellular levels of cyclin B1 protein and attenuating the activity of the cyclin B1 promoter [S.A. Innocente, J.L. Abrahamson, J.P. Cogswell, J.M. Lee, p53 regulates a G2 checkpoint through cyclin B1, Proc. Natl. Acad. Sci. USA 96 (1999) 2147-2152]. The ability of p53 to control mitotic initiation by regulating intracellular cyclin B1 levels suggests that a cyclin B1-dependent G2 checkpoint has a role in preventing neoplastic transformation. Here, we show that p53-mediated attenuation of the cyclin B1 promoter occurs in both p21+/+ and p21-/- cell lines. Furthermore, promoter attenuation is dependent on the presence of functional Sp1 binding sites and is independent of the NF-Y binding sites. We also find that wild-type, but not mutant, p53 protein binds Sp1 and the cyclin B1 promoter. This suggests that wild-type p53 mediates transcriptional repression of cyclin B1 through the Sp1 transcription factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710382     DOI: 10.1016/j.febslet.2004.12.073

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  43 in total

1.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Identification of primary transcriptional regulation of cell cycle-regulated genes upon DNA damage.

Authors:  Tong Zhou; Jeff Chou; Thomas E Mullen; Rani Elkon; Yingchun Zhou; Dennis A Simpson; Pierre R Bushel; Richard S Paules; Edward K Lobenhofer; Patrick Hurban; William K Kaufmann
Journal:  Cell Cycle       Date:  2007-04-19       Impact factor: 4.534

3.  Minute Virus of Mice Inhibits Transcription of the Cyclin B1 Gene during Infection.

Authors:  Matthew S Fuller; Kinjal Majumder; David J Pintel
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene.

Authors:  Yutaka Maeda; Wendy W Hwang-Verslues; Gang Wei; Takuya Fukazawa; Mary L Durbin; Laurie B Owen; Xuan Liu; Frances M Sladek
Journal:  Biochem J       Date:  2006-12-01       Impact factor: 3.857

5.  Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.

Authors:  O Vondálová Blanářová; I Jelínková; A Hyršlová Vaculová; P Sova; J Hofmanová; A Kozubík
Journal:  Cell Prolif       Date:  2013-09-30       Impact factor: 6.831

6.  Interplay between p53 and Ink4c in spermatogenesis and fertility.

Authors:  Hassan Zalzali; Wissam Rabeh; Omar Najjar; Rami Abi Ammar; Mohamad Harajly; Raya Saab
Journal:  Cell Cycle       Date:  2018-02-22       Impact factor: 4.534

Review 7.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

8.  Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis.

Authors:  Olga Fedorova; Alexey Petukhov; Alexandra Daks; Oleg Shuvalov; Tatyana Leonova; Elena Vasileva; Nikolai Aksenov; Gerry Melino; Nikolai A Barlev
Journal:  Oncogene       Date:  2018-11-19       Impact factor: 9.867

9.  Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology.

Authors:  Neil Benson; Tomomi Matsuura; Sergey Smirnov; Oleg Demin; Hannah M Jones; Pinky Dua; Piet H van der Graaf
Journal:  Interface Focus       Date:  2013-04-06       Impact factor: 3.906

10.  Effect of hydroxyurea on the promoter occupancy profiles of tumor suppressor p53 and p73.

Authors:  Vera Huang; Xin Lu; Yong Jiang; Jean Y J Wang
Journal:  BMC Biol       Date:  2009-06-26       Impact factor: 7.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.